Crystal Structure of the Peroxisome Proliferator-Activated Receptor gamma (PPARgamma) Ligand Binding Domain Complexed with a Novel Partial Agonist: A New Region of the Hydrophobic Pocket Could Be Exploited for Drug DesignSaccoccia, F., Scotti, E., Crestani, M., Godio, C., Gilardi, F., Loiodice, F., Fracchiolla, G., Laghezza, A., Tortorella, P., Lavecchia, A., Novellino, E., Mazza, F., Aschi, M., Pochetti, G., Montanari, R.
(2008) J.Med.Chem. 51: 7768-7776
- PubMed: 19053776
- DOI: 10.1021/jm800733h
- Primary Citation of Related Structures:
- Also Cited By: 4O8F, 4L98, 4L96, 6F2L, 4E4Q, 4E4K, 3HOD, 3HO0
- PubMed Abstract:
- Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors
Xu, H.E.,Lambert, M.H.,Montana, V.G.,Plunket, K.D.,Moore, L.B.,Collins, J.L.,Oplinger, J.A.,Kliewer, S.A.,Gampe, R.T.,McKee, D.D.,Moore, J.T.,Willson, T.M.
(2001) Proc.Natl.Acad.Sci.Usa 98: 13919
- Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors
Gampe, R.T.,Montana, V.G.,Lambert, M.H.,Miller, A.B.,Bledsoe, R.K.,Milburn, M.V.,Kliewer, S.A.,Willson, T.M.,Xu, H.E.
(2000) Mol.Cell 5: 545
- Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma
Nolte, R.T.,Wisely, G.B.,Westin, S.,Cobb, J.E.,Lambert, M.H.,Kurokawa, R.,Rosenfeld, M.G.,Willson, T.M.,Glass, C.K.,Milburn, M.V.
(1998) Nature 395: 137
The peroxisome proliferator-activated receptors (PPARs) are ligand-dependent transcription factors regulating glucose and lipid metabolism. The search for new PPAR ligands with reduced adverse effects with respect to the marketed antidiabetic agents ...
The peroxisome proliferator-activated receptors (PPARs) are ligand-dependent transcription factors regulating glucose and lipid metabolism. The search for new PPAR ligands with reduced adverse effects with respect to the marketed antidiabetic agents thiazolidinediones (TZDs) and the dual-agonists glitazars is highly desired. We report the crystal structure and activity of the two enantiomeric forms of a clofibric acid analogue, respectively complexed with the ligand-binding domain (LBD) of PPARgamma, and provide an explanation on a molecular basis for their different potency and efficacy against PPARgamma. The more potent S-enantiomer is a dual PPARalpha/PPARgamma agonist which presents a partial agonism profile against PPARgamma. Docking of the S-enantiomer in the PPARalpha-LBD has been performed to explain its different subtype pharmacological profile. The hypothesis that partial agonists show differential stabilization of helix 3, when compared to full agonists, is also discussed. Moreover, the structure of the complex with the S-enantiomer reveals a new region of the PPARgamma-LBD never sampled before by other ligands.
Consiglio Nazionale delle Ricerche, Roma 00016, Italy.